Ongoing with current combinations of antiretroviral drugs for the treatment of Human Immunodeficiency Virus (HIV) infection can successfully maintain long-term suppression of HIV-1 replication in plasma. Still, none of these therapies is capable of extinguishing the virus from the long-lived cellular reservoir, including monocyte-derived macrophages (MDM), that means the principal obstacle to HIV cure. MDM are widely distributed in all tissues and organs, including central system nervous (CNS) where they represent the most frequent HIV-infected cells that means the principal obstacle to HIV cure. Current FDA-approved antiretroviral drugs target viral reverse transcriptase, protease, integrase, and entry processes (coreceptor or fusion blockade). It is desirable to continue to develop new antiretrovirals directed against alternative targets in the virus lifecycle in order to further optimize therapeutic options, overcome resistance to existing medications, and potentially contribute to the elimination of viral reservoirs.This review provides a comprehensive overview of the activity of antiretroviral drugs (classical and upcoming) in monocytes-derived macrophages (MDM). Defining the antiviral activity of these drugs in this important cellular HIV-1 reservoir provides crucial hints about their efficacy in HIV-1 infected patients.

中文翻译：

---

不同细胞储库中抗逆转录病毒药物的潜在机制，重点是巨噬细胞。

目前正在使用的抗逆转录病毒药物组合治疗人类免疫缺陷病毒（HIV）感染可以成功维持血浆中HIV-1复制的长期抑制。尽管如此，这些疗法均无法从包括单核细胞衍生的巨噬细胞（MDM）在内的长寿细胞贮存库中扑灭病毒，这是治愈HIV的主要障碍。MDM广泛分布在所有组织和器官中，包括中枢神经系统（CNS），它们代表了HIV感染最频繁的细胞，这是治愈HIV的主要障碍。当前FDA批准的抗逆转录病毒药物靶向病毒逆转录酶，蛋白酶，整合酶和进入过程（共受体或融合阻滞）。希望继续开发针对病毒生命周期中其他目标的新抗逆转录病毒药物，以进一步优化治疗选择，克服对现有药物的耐药性并可能有助于消除病毒库。单核细胞衍生的巨噬细胞（MDM）中的抗逆转录病毒药物（经典药物和即将上市的药物）。在这种重要的细胞HIV-1储库中定义这些药物的抗病毒活性可提供有关其对HIV-1感染患者疗效的关键提示。这篇综述全面概述了单核细胞衍生巨噬细胞（MDM）中抗逆转录病毒药物的活性。在这种重要的细胞HIV-1储库中定义这些药物的抗病毒活性可提供有关其对HIV-1感染患者疗效的关键提示。这篇综述全面概述了单核细胞衍生巨噬细胞（MDM）中抗逆转录病毒药物的活性。在这种重要的细胞HIV-1储库中定义这些药物的抗病毒活性可提供有关其对HIV-1感染患者疗效的关键提示。